Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ismail Simsek

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritisYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patientsYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Rheumatology and Therapy|October 30, 2023
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm StudyMark S Fineman, Timothy E McAlindon, Christian Lattermann, et al.
Journal of Extracellular Vesicles|March 23, 2017
Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet's disease severityTamer Kahraman, Gozde Gucluler, Ismail Simsek, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 21, 2020
Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized TrialYusuf Yazici, Timothy E McAlindon, Allan Gibofsky, et al.
Rheumatology International|July 19, 2013
A polymorphism in ERAP1 is associated with susceptibility to ankylosing spondylitis in a Turkish populationMuhammet Cinar, Hatice Akar, Sedat Yilmaz, et al.
Clinical and Experimental Rheumatology|October 30, 2012
Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based studyIngmar A F M Heijnen, C Foocharoen, Bettina Bannert, et al.
Annals of the Rheumatic Diseases|June 17, 2010
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnthony J Tyndall, Bettina Bannert, Madelon Vonk, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritisYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patientsYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Rheumatology and Therapy|October 30, 2023
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm StudyMark S Fineman, Timothy E McAlindon, Christian Lattermann, et al.
Journal of Extracellular Vesicles|March 23, 2017
Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet's disease severityTamer Kahraman, Gozde Gucluler, Ismail Simsek, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 21, 2020
Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized TrialYusuf Yazici, Timothy E McAlindon, Allan Gibofsky, et al.
Rheumatology International|July 19, 2013
A polymorphism in ERAP1 is associated with susceptibility to ankylosing spondylitis in a Turkish populationMuhammet Cinar, Hatice Akar, Sedat Yilmaz, et al.
Clinical and Experimental Rheumatology|October 30, 2012
Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based studyIngmar A F M Heijnen, C Foocharoen, Bettina Bannert, et al.
Annals of the Rheumatic Diseases|June 17, 2010
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnthony J Tyndall, Bettina Bannert, Madelon Vonk, et al.
Pageof 7